Cardiff Net Receivables vs Net Working Capital Analysis

CRDF Stock

USD 2.64 0.27 11.39%

Cardiff Oncology financial indicator trend analysis is way more than just evaluating Cardiff Oncology prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cardiff Oncology is a good investment. Please check the relationship between Cardiff Oncology Net Receivables and its Net Working Capital accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiff Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

For more detail on how to invest in Cardiff Stock please use our How to Invest in Cardiff Oncology guide.

Net Receivables vs Net Working Capital

Net Receivables vs Net Working Capital Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cardiff Oncology Net Receivables account and Net Working Capital. At this time, the significance of the direction appears to have strong relationship.

The correlation between Cardiff Oncology's Net Receivables and Net Working Capital is 0.77. Overlapping area represents the amount of variation of Net Receivables that can explain the historical movement of Net Working Capital in the same time period over historical financial statements of Cardiff Oncology, assuming nothing else is changed. The correlation between historical values of Cardiff Oncology's Net Receivables and Net Working Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Receivables of Cardiff Oncology are associated (or correlated) with its Net Working Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Working Capital has no effect on the direction of Net Receivables i.e., Cardiff Oncology's Net Receivables and Net Working Capital go up and down completely randomly.

Correlation Coefficient

0.77

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Net Receivables

Net Working Capital

Most indicators from Cardiff Oncology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cardiff Oncology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiff Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

For more detail on how to invest in Cardiff Stock please use our How to Invest in Cardiff Oncology guide.The current Selling General Administrative is estimated to decrease to about 7.9 M. The current Issuance Of Capital Stock is estimated to decrease to about 27.6 M

	2024	2025 (projected)
Non Recurring	598.2K	531.7K
Reconciled Depreciation	404K	453.9K

Non Recurring Reconciled Depreciation

Cardiff Oncology fundamental ratios Correlations

	Total Assets	Total Stockholder Equity	Net Debt	Cash	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Stockholder Equity	Total Current Assets	Common Stock	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Property Plant And Equipment Net	Retained Earnings	Accounts Payable	Non Current Assets Total	Non Currrent Assets Other	Net Receivables	Non Current Liabilities Total	Other Current Assets	Total Liab	Property Plant And Equipment Gross	Short Term Debt	Common Stock Total Equity	Inventory	Net Tangible Assets
Total Assets		0.96	-0.55	0.56	0.96	0.67	0.76	0.96	-0.29	0.02	0.55	0.54	0.57	-0.63	0.35	0.53	-0.11	0.64	-0.17	0.84	0.19	0.47	0.08	-0.26	0.47	0.87
Total Stockholder Equity	0.96		-0.57	0.5	0.99	0.79	0.84	0.99	-0.22	-0.14	0.63	0.61	0.49	-0.71	0.46	0.45	-0.19	0.75	-0.33	0.84	0.05	0.52	0.0	-0.16	0.5	0.95
Net Debt	-0.55	-0.57		-0.96	-0.6	-0.23	-0.43	-0.59	0.22	-0.01	-0.35	-0.38	-0.02	0.33	-0.29	0.0	0.6	-0.27	0.1	-0.13	-0.13	-0.17	-0.12	0.22	-0.28	-0.53
Cash	0.56	0.5	-0.96		0.56	0.1	0.32	0.54	-0.24	0.21	0.25	0.32	0.09	-0.22	0.18	0.08	-0.52	0.13	0.1	0.1	0.29	0.1	0.26	-0.3	0.24	0.43
Cash And Short Term Investments	0.96	0.99	-0.6	0.56		0.76	0.84	1.0	-0.29	-0.02	0.65	0.66	0.52	-0.71	0.5	0.49	-0.16	0.74	-0.21	0.8	0.19	0.56	0.07	-0.24	0.49	0.94
Common Stock Shares Outstanding	0.67	0.79	-0.23	0.1	0.76		0.88	0.77	-0.03	-0.33	0.84	0.79	0.41	-0.87	0.73	0.41	0.07	0.89	-0.52	0.74	-0.04	0.77	-0.18	0.03	0.46	0.9
Other Stockholder Equity	0.76	0.84	-0.43	0.32	0.84	0.88		0.84	-0.39	-0.22	0.91	0.83	0.59	-0.98	0.7	0.55	-0.08	0.88	-0.45	0.77	0.06	0.82	-0.13	0.09	0.67	0.88
Total Current Assets	0.96	0.99	-0.59	0.54	1.0	0.77	0.84		-0.29	-0.03	0.66	0.66	0.53	-0.71	0.51	0.5	-0.15	0.75	-0.22	0.81	0.18	0.56	0.07	-0.23	0.49	0.95
Common Stock	-0.29	-0.22	0.22	-0.24	-0.29	-0.03	-0.39	-0.29		-0.1	-0.32	-0.19	-0.38	0.34	-0.14	-0.38	-0.06	-0.25	-0.16	-0.24	-0.26	-0.3	0.17	0.13	-0.22	-0.18
Short Long Term Debt Total	0.02	-0.14	-0.01	0.21	-0.02	-0.33	-0.22	-0.03	-0.1		-0.08	0.14	0.37	0.25	0.0	0.4	0.35	-0.3	0.9	-0.15	0.9	0.04	0.78	-0.39	-0.05	-0.23
Other Current Liab	0.55	0.63	-0.35	0.25	0.65	0.84	0.91	0.66	-0.32	-0.08		0.93	0.56	-0.94	0.79	0.55	0.08	0.77	-0.3	0.54	0.24	0.94	-0.1	0.04	0.56	0.75
Total Current Liabilities	0.54	0.61	-0.38	0.32	0.66	0.79	0.83	0.66	-0.19	0.14	0.93		0.59	-0.84	0.85	0.56	0.1	0.74	-0.13	0.48	0.44	0.93	0.23	-0.03	0.57	0.73
Property Plant And Equipment Net	0.57	0.49	-0.02	0.09	0.52	0.41	0.59	0.53	-0.38	0.37	0.56	0.59		-0.58	0.22	0.97	0.43	0.41	0.14	0.67	0.48	0.68	0.35	-0.07	0.67	0.41
Retained Earnings	-0.63	-0.71	0.33	-0.22	-0.71	-0.87	-0.98	-0.71	0.34	0.25	-0.94	-0.84	-0.58		-0.71	-0.54	0.02	-0.85	0.49	-0.71	-0.03	-0.87	0.16	-0.2	-0.7	-0.79
Accounts Payable	0.35	0.46	-0.29	0.18	0.5	0.73	0.7	0.51	-0.14	0.0	0.79	0.85	0.22	-0.71		0.2	0.04	0.76	-0.16	0.32	0.3	0.74	-0.01	-0.03	0.24	0.62
Non Current Assets Total	0.53	0.45	0.0	0.08	0.49	0.41	0.55	0.5	-0.38	0.4	0.55	0.56	0.97	-0.54	0.2		0.54	0.38	0.21	0.65	0.52	0.67	0.31	-0.18	0.57	0.38
Non Currrent Assets Other	-0.11	-0.19	0.6	-0.52	-0.16	0.07	-0.08	-0.15	-0.06	0.35	0.08	0.1	0.43	0.02	0.04	0.54		0.01	0.42	0.13	0.44	0.31	0.16	-0.36	-0.14	-0.14
Net Receivables	0.64	0.75	-0.27	0.13	0.74	0.89	0.88	0.75	-0.25	-0.3	0.77	0.74	0.41	-0.85	0.76	0.38	0.01		-0.45	0.75	0.0	0.69	-0.19	0.05	0.48	0.83
Non Current Liabilities Total	-0.17	-0.33	0.1	0.1	-0.21	-0.52	-0.45	-0.22	-0.16	0.9	-0.3	-0.13	0.14	0.49	-0.16	0.21	0.42	-0.45		-0.35	0.83	-0.17	0.58	-0.59	-0.34	-0.41
Other Current Assets	0.84	0.84	-0.13	0.1	0.8	0.74	0.77	0.81	-0.24	-0.15	0.54	0.48	0.67	-0.71	0.32	0.65	0.13	0.75	-0.35		-0.02	0.5	-0.07	0.02	0.55	0.76
Total Liab	0.19	0.05	-0.13	0.29	0.19	-0.04	0.06	0.18	-0.26	0.9	0.24	0.44	0.48	-0.03	0.3	0.52	0.44	0.0	0.83	-0.02		0.36	0.65	-0.54	0.03	0.04
Property Plant And Equipment Gross	0.47	0.52	-0.17	0.1	0.56	0.77	0.82	0.56	-0.3	0.04	0.94	0.93	0.68	-0.87	0.74	0.67	0.31	0.69	-0.17	0.5	0.36		0.07	-0.02	0.59	0.65
Short Term Debt	0.08	0.0	-0.12	0.26	0.07	-0.18	-0.13	0.07	0.17	0.78	-0.1	0.23	0.35	0.16	-0.01	0.31	0.16	-0.19	0.58	-0.07	0.65	0.07		-0.19	0.2	-0.09
Common Stock Total Equity	-0.26	-0.16	0.22	-0.3	-0.24	0.03	0.09	-0.23	0.13	-0.39	0.04	-0.03	-0.07	-0.2	-0.03	-0.18	-0.36	0.05	-0.59	0.02	-0.54	-0.02	-0.19		0.44	-0.13
Inventory	0.47	0.5	-0.28	0.24	0.49	0.46	0.67	0.49	-0.22	-0.05	0.56	0.57	0.67	-0.7	0.24	0.57	-0.14	0.48	-0.34	0.55	0.03	0.59	0.2	0.44		0.49
Net Tangible Assets	0.87	0.95	-0.53	0.43	0.94	0.9	0.88	0.95	-0.18	-0.23	0.75	0.73	0.41	-0.79	0.62	0.38	-0.14	0.83	-0.41	0.76	0.04	0.65	-0.09	-0.13	0.49

Click cells to compare fundamentals

Cardiff Oncology Account Relationship Matchups

Cardiff Oncology fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	134.7M	149.5M	116.2M	81.6M	97.2M	48.7M
Total Stockholder Equity	128.2M	140.4M	106.3M	69.7M	82.9M	87.1M
Net Debt	(130.1M)	(8.8M)	(13.6M)	(19.5M)	(49.9M)	(47.4M)
Cash	131.0M	11.9M	16.3M	21.7M	51.5M	26.1M
Cash And Short Term Investments	131.0M	140.8M	105.3M	74.8M	91.7M	96.3M
Common Stock Shares Outstanding	20.9M	39.0M	43.6M	44.7M	47.7M	50.0M
Liabilities And Stockholders Equity	134.7M	149.5M	116.2M	81.6M	97.2M	48.7M
Other Stockholder Equity	359.6M	400.4M	404.8M	409.3M	467.1M	490.4M
Total Current Assets	133.4M	146.1M	111.3M	77.4M	95.1M	99.8M
Common Stock	7.7K	8.3K	3.7K	4K	7K	6.7K
Short Long Term Debt Total	869.5K	3.1M	2.7M	2.1M	1.5M	1.4M
Other Current Liab	3.9M	4.0M	4.5M	7.8M	7.9M	8.3M
Total Current Liabilities	6.1M	6.6M	7.8M	10.4M	13.4M	14.1M
Property Plant And Equipment Net	966.7K	3.2M	3.5M	2.9M	2.1M	1.8M
Retained Earnings	(231.5M)	(259.8M)	(298.1M)	(339.5M)	(384.2M)	(365.0M)
Accounts Payable	1.4M	1.4M	2.0M	2.0M	4.8M	5.1M
Non Current Assets Total	1.4M	3.4M	4.9M	4.2M	2.1M	2.3M
Net Receivables	320.5K	535K	771K	288K	773K	811.7K
Non Current Liabilities Total	450.5K	2.6M	2.0M	1.5M	813K	772.4K
Other Current Assets	2.1M	4.8M	5.2M	2.3M	2.5M	1.6M
Total Liab	6.6M	9.1M	9.8M	11.9M	14.2M	11.4M
Property Plant And Equipment Gross	966.7K	3.2M	3.5M	6.7M	6.2M	6.5M
Accumulated Other Comprehensive Income	(2.2M)	(142K)	(395K)	(67K)	34K	35.7K
Short Term Debt	860K	1.1M	1.4M	691K	710K	1.3M
Common Stock Total Equity	7.7K	8.3K	3.7K	4K	4.6K	4.7K
Net Tangible Assets	7.3M	128.2M	140.4M	106.3M	122.3M	128.4M
Retained Earnings Total Equity	(208.9M)	(231.5M)	(259.8M)	(298.1M)	(268.3M)	(281.7M)
Capital Surpluse	217.2M	361.8M	400.5M	404.8M	465.6M	249.6M
Property Plant Equipment	877.8K	623.7K	382K	1.3M	1.1M	1.2M
Other Assets	404.2K	239K	1.4M	1.0	0.9	0.86
Net Invested Capital	128.2M	140.4M	106.3M	69.7M	82.9M	76.0M
Net Working Capital	127.2M	139.6M	103.5M	67.0M	81.6M	74.4M

Currently Active Assets on Macroaxis

USOI	Credit Suisse X Links
ULTY	Tidal Trust II
CONY	YieldMax N Option
BCAT	BlackRock Capital Allocation
PDI	Pimco Dynamic Income

When determining whether Cardiff Oncology is a strong investment it is important to analyze Cardiff Oncology's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cardiff Oncology's future performance. For an informed investment choice regarding Cardiff Stock, refer to the following important reports:

How To Invest In Cardiff

Details

Is Cardiff Stock a good investment?

Details

What is Cardiff Oncology's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiff Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

For more detail on how to invest in Cardiff Stock please use our How to Invest in Cardiff Oncology guide.

You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardiff Oncology. If investors know Cardiff will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardiff Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.87)

Revenue Per Share

0.009

Quarterly Revenue Growth

(0.26)

Return On Assets

(0.48)

Return On Equity

(0.92)

The market value of Cardiff Oncology is measured differently than its book value, which is the value of Cardiff that is recorded on the company's balance sheet. Investors also form their own opinion of Cardiff Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cardiff Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardiff Oncology's market value can be influenced by many factors that don't directly affect Cardiff Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Cardiff Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardiff Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiff Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC

Cardiff Net Receivables vs Net Working Capital Analysis

Net Receivables vs Net Working Capital

Net Receivables vs Net Working Capital Correlation Analysis

Correlation Coefficient

Net Receivables

Net Working Capital

Cardiff Oncology fundamental ratios Correlations

Cardiff Oncology Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cardiff Oncology fundamental ratios Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Cash And Short Term Investments
Cash And Short Term Investments	+ 0.99	Total Stockholder Equity
Total Current Assets	+ 0.99	Total Stockholder Equity
Non Current Assets Total	+ 0.97	Property Plant And Equipment Net
Total Stockholder Equity	+ 0.96	Total Assets
Cash And Short Term Investments	+ 0.96	Total Assets

Retained Earnings	- 0.98	Other Stockholder Equity
Cash	- 0.96	Net Debt
Retained Earnings	- 0.94	Other Current Liab
Property Plant And Equipment Gross	- 0.87	Retained Earnings
Retained Earnings	- 0.87	Common Stock Shares Outstanding
Net Receivables	- 0.85	Retained Earnings